Assertio Holdings (ASRT) Long-Term Deferred Tax (2022 - 2023)

Assertio Holdings' (ASRT) quarterly Long-Term Deferred Tax came in at $81.6 million in Q2 2023, little changed quarter-over-quarter from $81.6 million in Q1 2023.

Assertio Holdings (ASRT) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends

Assertio Holdings has disclosed Long-Term Deferred Tax across 2 years of filings, most recently posting $81.6 million for Q2 2023.

  • Long-Term Deferred Tax for Q2 2023 came in at $81.6 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $81.6 million (changed N/A YoY), and the FY2022 annual result was $80.2 million, changed N/A from the prior year.
  • Long-Term Deferred Tax came in at $81.6 million for Q2 2023 at Assertio Holdings, roughly flat from $81.6 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $81.6 million in Q2 2023 to a low of $80.2 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Assertio Holdings 150.94 Mn 79.37 Mn 7.22 Mn

Historic Data

Download Data
DateValue
Jun 30, 2023 81.59 Mn
Mar 31, 2023 81.57 Mn
Dec 31, 2022 80.20 Mn